Teva Pharma (TEVA) Reports In-Line Q4 EPS

Teva Pharma (NYSE: TEVA) reported Q4 EPS of $1.31, in-line with the analyst estimate of $1.31. Revenue for the quarter came in at $5.17 billion versus the consensus estimate of $5.17 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance